Bispecific antibody · Immune activation, directed at CD20 (MS4A1) and CD3 receptor (CD3E) · developed by Genmab Us
Epcoritamab is a bispecific CD20-directed CD3 T-cell engaging antibody. It binds CD3 on T-cells and CD20 on B-lineage lymphoma cells, bringing the two together so T-cells lyse the B-cells. It is studied in B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 22, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05578976 | Phase 3 | Diffuse Large B-Cell Lymphoma | Active not recruiting | GMAB |
| NCT04542824 | Phase 1/2 | Diffuse Large B Cell Lymphoma | Active not recruiting | GMAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Large B Cell LymphomaFollicular LymphomaHigh-grade B-cell LymphomaMarginal Zone LymphomaPrimary Mediastinal Large B Cell LymphomaSmall Lymphocytic Lymphoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.
See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GMAB catalysts and pipeline →